Bevacizumab (a monoclonal antibody that targets VEGF) and aflibercept (a recombinant fusion protein that binds strongly to VEGF) are being explored clinically to block VEGF pathways in NSCLC patients [33,34]. Here, VEGFA is linked to non-small cell lung carcinoma.